

Writing a Protocol

Workshop Series for Clinical Research Professionals

Avni Bhatt, PhD

Division of Hospital Medicine
Department of Pediatrics
University of Florida

Pawandeep Kaur, MPH

Department of Global Health
Boston University School of
Public Health



The University of Vermont
LARNER COLLEGE OF MEDICINE

Outline for today

Today's Agenda

Activity

Trial Basics

Developing a research question

Activity

Protocol Details

Informed Consent

Activity

Resources at each institution

Overview of protocol

What is a protocol?

Document that details the study rationale, proposed methods, organization and ethical considerations

Purpose:

- For trial investigators and staff use protocols- to **document plans for study conduct** at all stages from participant recruitment to results dissemination
- For funding agencies, IRBs, regulatory agencies, and other groups- to **appraise the conduct and reporting** of clinical trials.

General considerations:

- Consider local requirements for multi-site/global studies
- Consider resources and processes at sites for multi-site/global studies
eg: equipment available, supplies etc.

What does it take to write a good study protocol?



5 minutes

Huddle into groups of 3 – 4 and introduce yourself briefly

Activity 1

- What's missing?

Introduction

Objectives

Trial Design

Study setting

Participants

Interventions

Participant
timeline

Sample size

Recruitment

Randomization

Blinding

Data

Data collection
methods

Data management

Outcomes
(1° and 2°)

Interim analysis

Monitoring

Data monitoring

Auditing

Ethics

Confidentiality

Access to data

Ancillary and
post-trial care

Publication policy

What does it take to write a good study protocol?



5 minutes

Answer

Introduction

Background and rationale

Objectives

Trial Design

Study setting

Participants

Inclusion criteria

Interventions

Participant timeline

Sample size

Recruitment

Randomization

Blinding

Data

Data collection methods

Data management

Outcomes (1° and 2°)

Statistical methods

Interim analysis

Monitoring

Data monitoring

Harms/Adverse events

Auditing

Ethics

Consent and assent

Confidentiality

Access to data

Ancillary and post-trial care

Publication policy

Types of trials

Meta-Analysis

Systematic Review

Randomized Controlled Trial

Cohort Study (Prospective Observational Study)

Case-control Study

Cross-sectional study

Case Reports and Series



Note: Not all types of trials require all components of the protocol

Developing a good research question

A clinical study involves research using human volunteers that is intended to **add to medical knowledge**.

Interest: Want to know more about hand-washing technique in children

What is a research question that addresses all 4 points?




Developing a good research question

Interest: Want to know more about hygiene practices in children

Question: How long do children wash their hands when asked to do so at the end of a regularly scheduled well-check appointment?



Defined start and stop time for hand-washing



Prior research establishes that hand washing time relates to overall hygiene



Study staff will...

- Consent parent/child at well-check appointment
- Ask caregiver to record time with provided stopwatch
- Only ask for one recording



Focusing on hand-washing practice in children


Developing your own research questions!



5 minutes

Activity 2

- As a group, pick a research study that you are working on
- Develop a research question
- List qualities of the question that fit in each category below




Developing your own research questions!




5 minutes

Let's hear from one group at each institution




The intro bits

Background and Objective



The intro bits

Finding medical literature



Format: Abstract ▾

[BMC Public Health](#). 2019 Apr 11;19(1):398. doi: 10.1186/s12889-019-6729-x.

Visibility and transmission: complexities around promoting hand hygiene in young children - a qualitative study.

[Biezen R¹](#), [Grando D²](#), [Mazza D³](#), [Brijnath B⁴](#).

Author information

- 1 Department of General Practice, Monash University, Building 1, 270 Ferntree Gully Road, Notting Hill, VIC, 3168, Australia. ruby.biezen@gmail.com.
- 2 School of Science, RMIT University, Building 223, Level 1, Bundoora Campus, Plenty Road, Bundoora, VIC, 3083, Australia.
- 3 Department of General Practice, Monash University, Building 1, 270 Ferntree Gully Road, Notting Hill, VIC, 3168, Australia.
- 4 National Ageing Research Institute LTD, 34-54 Poplar Road, Parkville, VIC, 3052, Australia.

Full text links

Read free full text at [BMC](#) [PMC](#) [FREE Full text](#)

Save items

☆ Add to Favorites ▾

Similar articles

Management of respiratory tract infections in young children [NPJ Prim Care Respir Med. 2017]

The intro bits



Using a citation manager

A screenshot of a web browser showing a PubMed article page. The URL is ncbi.nlm.nih.gov/pubmed/30975108. The article title is 'Visibility and transmission: complexities around promoting hand hygiene in young children - a qualitative study.' by Biezen R¹, Grando D², Mazza D³, Brijnath B⁴. The Zotero Connector overlay is visible in the top right corner, showing a 'Saving to' dropdown menu set to 'Hand Hygiene Project'. The overlay also lists 'Full text links' (Read free full text at BMC, PMC Full text) and 'Save items' (Add to Favorites).

ncbi.nlm.nih.gov/pubmed/30975108

NCBI Resources How To Sign in to NCBI

PubMed.gov PubMed Advanced

US National Library of Medicine National Institutes of Health

Format: Abstract Send to

BMC Public Health. 2019 Apr 11;19(1):398. doi: 10.1186/s12889-019-6729-x.

Visibility and transmission: complexities around promoting hand hygiene in young children - a qualitative study.

Biezen R¹, Grando D², Mazza D³, Brijnath B⁴.

Author information

- 1 Department of General Practice, Monash University, Building 1, 270 Ferntree Gully Road, Notting Hill, VIC, 3168, Australia. ruby.biezen@gmail.com.
- 2 School of Science, RMIT University, Building 223, Level 1, Bundoora Campus, Plenty Road, Bundoora, VIC, 3083, Australia.
- 3 Department of General Practice, Monash University, Building 1, 270 Ferntree Gully Road, Notting Hill, VIC, 3168, Australia.
- 4 National Ageing Research Institute LTD, 34-54 Poplar Road, Parkville, VIC, 3052, Australia.

Saving to Hand Hygiene Project

Visibility and transmission: complexities around pr...

PubMed entry

Open-Access PDF

Full text links

Read free full text at BMC PMC Full text

Save items


Add to Favorites

Similar articles

Management of respiratory tract infections in young childrer [NPJ Prim Care Respir Med. 2017]


The intro bits

Using a citation manager



The intro bits

Writing a strong objective statement



Participant info

Inclusion criteria

- Criteria should be narrow enough to keep the study population relatively homogenous
- But not so narrow that enrollment is unrealistic
- PI and CRC should collaborate to ensure access to subject pool

**Chart review
to screen for
eligible
subjects**

→ “Preparatory
research” falls
under HIPAA Act
of 1996



Timeline


A clear and concise timeline:

- Can help guide trial conduct
- Enable external review of participant burden and feasibility
- It outlines the patient's experience at each study visit
- Can be used as a quick reference during patient visits as a checklist

Key information:

- Timing of each visit, starting from initial eligibility screening to study close-out
- Time periods of administration of trial intervention
- List of assessments performed on participants at each visit
- Any exceptions to the assessments

Timeline



Timeline

Treatment periods	Pre-treatment		Treatment visits (Wk 2, wk 4, and every 4 weeks after until treatment completion)											Post treatment follow up (every 12 wks until wk 76)			Final Visit			
Visit	1 Screening	2 Baseline	2a	3	3a	4	4a	4b	4c	5	6	7	8	9	10	11	12	13	14	
Day/Week/Month	Day		Weeks																	
	14 to -1	0	1 ⁹	2	3 ⁹	4	5 ⁹	6 ⁹	7 ⁹	8	12	16	20	24	28	32	36	40	44	
Consent	X																			
Medical History ¹	X			X		X				X	X	X	X	X	X	X	X	X	X	
Fundoscopic Exam ²	X			X		X				X										
Physical Exam	X			X		X				X	X	X								
Neurologic Exam ²	X			X		X				X										
HIV	X																			
HCV, HBV		X																		
CXR ³	X																			
12 Lead ECG & QTcF ⁴	X	X ⁸	X ⁹	X	X ⁹	X	X ⁹	X ⁹	X ⁹	X	X	X								
CBC ⁵	X	X		X		X				X	X	X								
Serum HCG ⁵	X			X		X				X	X	X								
Urine HCG ⁵		X																		
Blood Chemistry ⁴	X	X		X		X				X	X	X								

¹ Includes concomitant medications;

³ To be performed only if one is not available from within 2 months from screening

⁴ Until 4 weeks after last treatment visit.

⁵ Women of childbearing age.

Data collection and management

Excellent for prospective studies:

- Surveys
- Subject data entry
- Longitudinal studies



Demographics and History

+ Adding new Record ID 1

Event Name: **Visit 1: Baseline**

Record ID

1

Date of Enrollment

* must provide value



Today

M-D-Y

Birth Date:

* must provide value



Today

M-D-Y

Ethnicity

* must provide value



- ☐ Hispanic or Latino
- ☐ Non Hispanic or Latino
- ☐ Declined

reset

- ☐ White
- ☐ Black or African American

Data collection and management

Excellent for prospective studies:

- Surveys
- Subject data entry
- Longitudinal studies



NEW Record ID 1

 Data Collection Instrument	Visit 1: Baseline	Visit 2: 3 Months	Visit 3: 6 Months	Visit 4: 9 Months	Visit 5: 12 Months
Demographics and History	☐				
9-5-2-1-0 Screener	☐	☐	☐	☐	
Physical Exam	☐	☐	☐	☐	☐
Complete Blood Draw	☐		☐		☐
Imaging	☐				☐

For a retrospective study, Excel is acceptable

Outcomes

Primary outcome	Secondary outcomes
What do these data directly tell you that answers your question?	What else can you figure out now that you have these data?

Example

Question: How long do children wash their hands when asked to do so at the end of a regularly scheduled well-check appointment?

Primary	Secondary
Hand washing information	Age Race Ethnicity History of bacterial infections History of viral infections

Data monitoring

- Periodic inspection of the outcome data by study group is necessary for some trials.
- A trial should be modified or discontinued when the accumulated data have sufficiently disturbed the clinical equipoise that justified the trial.
- Certain trials warrant some form of data monitoring. Trials with a short duration or known minimal risks do not need a formal committee.

Data Monitoring Committee (DMC)

- Consists of members from a variety of disciplines
- To periodically review the data and determine if a trial should be modified or discontinued.
- Independent from sponsor and trial investigators “completely uninvolved in the running of the trial and who cannot be unfairly influenced (either directly or indirectly) by people, or institutions, involved in the trial.”

Data monitoring

- The protocol should name the chair and members of the DMC.
- If unknown, indicate intended size and characteristics, roles and responsibilities, planned method of functioning.
- A charter is recommended for detailing this information.

Interim analyses

- To formally monitor the accumulating data in clinical trials.
- They are generally performed in trials that have a DMC, longer duration of recruitment, and potentially serious outcomes.

The results of these analyses, along with non-statistical criteria, can be part of a stopping guideline that helps inform whether the trial should be continued, modified, or halted earlier than intended for benefit, harm, or futility.

Harms

Evaluation of harms enables monitoring of participants and appropriate management of adverse events

What to include in the protocol?

- Frequency of data collection, overall surveillance and instruments to be used.
- Distinguish between anticipated vs unanticipated, and solicited vs unsolicited.
- The reporting of harms to relevant regulatory groups, funders, and IRBs
- For multi-center studies, procedures and timings for central collection, evaluation, and reporting of pooled data
- How long after intervention are AEs being collected for?
- Definitions of SAEs, including conditions for discontinuation and the follow up required.

Relevant concomitant care

Comparable study groups should only differ by the intervention being evaluated, so any outcome differences can be attributed to effects of the intervention.

For comparability of study groups, protocol should list relevant concomitant care and interventions that are allowed, and those that are prohibited.

Be specific and include any lengths of times that the concomitant care is allowed for

Examples:

1. Rescue medication
2. In a multi-drug resistant TB trial, the background regimen

Writing Informed Consent

Main topics to get across:

- Voluntary
- Does not affect quality of care
- Risks/benefits

Understandable language for low health literacy and possibly in multiple languages.

Logistics:

- WHO will be obtaining consent
- WHERE it will be done
- HOW patients will be found (recruitment)

All this goes into the consent process and belongs in your protocol



Explaining Informed Consent

GUIDELINES FOR OBTAINING INFORMED CONSENT:

1. Always be sensitive and polite.

- Address the patient directly. “If you choose to participate, you would get an ultrasound of your liver, so we’ll put a probe here on your body and press a button to measure...”
- If the caregiver asks a question, use appropriate pronouns. If preferred pronouns are not listed in the patient’s chart, use they/their.
- If they say no, it is 100% okay. They can contact us later if they change their mind.

2. Be comfortable with the basic purpose of this study.

3. Know the logistical details of what the participant would be asked to do.

- Short survey at the start of each of their follow up appointments
- Parking at CTRB in the study participant spots → check in at desk for Dayton study
- Parking for MBI in north tower visitor lot → enter MBI main doors
- Payment for participation in form of Visa gift card
- Fibroscan takes ~30 mins and MRI takes ~1hr (at most)

Explaining Informed Consent

Overview of Consent Process	Example
Enter the room	*knock knock*
Introduce yourself	"My name is XXX and I am working with Dr. XXX on a study related to the health of transgender youth..."
Study aims in a couple <u>simple</u> sentences	"We are interested in how a person's liver and metabolism might be affected by XXX treatment..."
What the patient would do as a participant	"If you choose to participate, you would get an ultrasound of your liver, so we'll place a little probe here on your body and press a button to measure..."
Risks and benefits	"You might feel claustrophobic in the MRI, and it makes a loud noise. There are no direct benefits to you. You will be compensated for your participation..."
Say these sentences →	"This is completely voluntary and you can withdraw at any time. Saying yes or no will not affect your healthcare in any way."
Answer questions	"Do you have any questions?"
Assess interest	"Are you interested in participating?"
Consent and assent	"Since you are a minor, I need a signature from mom and you'll just say out loud that you agree to participate."
Give the patient a copy of the ICF	"Here's a copy of the consent form with our contact information."
Leave the room	"Thank you!"
Complete the consent checklist and file with ICF	

Explaining Informed Consent

To explain informed consent, you must understand:

- the protocol
- the investigator's priorities
- the subject's priorities
- potential compliance issues
- the subject's rights

		Yes	No	Date	Staff Initials
1	Discussed study with potential subject and caregiver.	☐	☐		
2	Copy of ICF given to subject and time for review and discussion was provided.	☐	☐		
3	The subject met all eligibility requirements	☐	☐		
4	The subject's verbal assent is documented on ICF.	☐	☐		
5	The caregiver signed and dated the ICF, and listed relationship to subject.	☐	☐		
6	Caregiver provided consent for subject to participate.	☐	☐		
7	Subject provided verbal assent to participate.	☐	☐		
8	ICF was signed and dated by IRB-approved research personnel	☐	☐		
9	Did the subject, parent/LAR, and study staff enter the same date on the ICF?	☐	☐		
10	ICF free of strikeouts or changes.	☐	☐		
11	Subject consented with valid, IRB-01 approved version of the ICF.	☐	☐		
12	Consent was obtained before initiation of study procedures or data collection.	☐	☐		
13	Original signed ICF on file	☐	☐		
14	Copy of ICF given to subject/family.	☐	☐		

Matching?



7 minutes

Activity 3: Match the sentence or phrase to the section of the protocol where it comes from

- a) Patients will be advised that participation is completely voluntary and will not affect routine care.
- b) Power analysis indicates an ideal study population of 40 trial and 40 control participants.
- c) Results of this study will also inform on the average age and demographics of patients attending well-check visits.
- d) The purpose of the study is to understand the sensitivity and specificity of procalcitonin levels as a measure of bacteremia.
- e) However, the incidence rate of cardiac arrest in geriatric heart transplant patients across the state is yet unknown.
- f) Individuals age 18-24 actively enrolled in an undergraduate institution will be eligible to participate.
- g) There is a chance of fall injury while performing gait assessments.
- h) While on the study, participants will receive monthly EKGs to monitor for drug-induced tachycardia.

Matching?



3 minutes

Answer

Consent

a) Patients will be advised that participation is completely voluntary and will not affect routine care.

Sample size

b) Power analysis indicates an ideal study population of 40 trial and 40 control participants.

2^o outcomes

c) Results of this study will also inform on the average age and demographics of patients attending well-check visits.

Objective

d) The purpose of the study is to understand the sensitivity and specificity of procalcitonin levels as a measure of bacteremia.

Background

e) However, the incidence rate of cardiac arrest in geriatric heart transplant patients across the state is yet unknown.

Inclusion criteria

f) Individuals age 18-24 actively enrolled in an undergraduate institution will be eligible to participate.

Risks

g) There is a chance of fall injury while performing gait assessments.

Timeline

h) While on the study, participants will receive monthly EKGs to monitor for drug-induced tachycardia.

Wrap up

A research protocol is a document that describes the...

- *Background*
 - *Rationale*
 - *Objectives*
 - *Design*
 - *Methodology*
 - *Statistical considerations*
 - *And organization*
- ...of a clinical research project.*

Resources

UF IRB-01 (Clinical):

<http://irb.ufl.edu/irb01/irb-01.html>

UF IRB-02 (Behavioral):

<http://irb.ufl.edu/irb02.html>

UF Biostatistics Research Design Program:

<https://www.ctsi.ufl.edu/about/ctsi-programs/research-design-and-analysis/>

Integrated Data Repository:

<https://idr.ufhealth.org/services/analyst-data-support-services/idr-data-request-form/>

NIH Protocol e-template:

<https://www.centerwatch.com/articles/24509-nih-online-tool-strengthens-protocol-collaboration>

SPIRIT checklist :

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ [Internet]. 2013 Jan 9 [cited 2020 Jan 14];346. Available from: <https://www.bmj.com/content/346/bmj.e7586>

UVM Local IRB resources:

<https://www.uvm.edu/rpo/uvmclick-irb-forms-library>

UVM Commons Site – OCTR Intranet resources:

<https://commons.med.uvm.edu/dean/comclntrl/SitePages/Regulatory%20Documents%20and%20Resources.aspx>

UVM Biomedical Statistics Research Core:

<https://www.uvm.edu/biostatistics>

BUMC Local IRB resources:

<http://www.bumc.bu.edu/irb/inspir-ii/irb-templates/>

BU CRRO:

<http://www.bumc.bu.edu/crrro/research-and-regulatory-consultations/>

BU library resources:

<http://www.bumc.bu.edu/medlib/services/research-help/>

Questions?



The University of Vermont
LARNER COLLEGE OF MEDICINE